Literature DB >> 7236716

Effect of piracetam on sickle erythrocytes and sickle hemoglobin.

T Asakura, S T Ohnishi, K Adachi, M Ozguc, K Hashimoto, M T Devlin, E Schwartz.   

Abstract

Piracetam, 2-oxo-1-pyrrolidine acetamide, inhibits sickling of red cells containing sickle hemoglobin (Hb S). The concentration required for 50% inhibition is about 300 mM. Addition of piracetam into the supersaturated Hb S solution in concentrated phosphate buffer prolongs the delay time prior to gelation. Piracetam shifts the oxygen equilibrium curves of blood toward the right, with a stronger effect at higher piracetam concentrations. Piracetam increases the viscosity of oxygenated cells but reduces the relative viscosity of deoxygenated sickle cells. The mechanism for the antisickling effect of piracetam will be discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7236716     DOI: 10.1016/0005-2795(81)90173-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Use of piracetam improves sickle cell deformability in vitro and in vivo.

Authors:  E K Gini; J Sonnet
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

2.  Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro.

Authors:  D Roa; P Kopsombut; M P Aguinaga; E A Turner
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment.

Authors:  G Chouinard; L Annable; A Ross-Chouinard; M Olivier; F Fontaine
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 4.  Piracetam for reducing the incidence of painful sickle cell disease crises.

Authors:  Amani Al Hajeri; Zbys Fedorowicz
Journal:  Cochrane Database Syst Rev       Date:  2016-02-12

Review 5.  Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Authors:  Olujide O Olubiyi; Maryam O Olagunju; Birgit Strodel
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.